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PEE8
QUALITY OF LIFE OF FRENCH PATIENTS 
TREATED FOR PRIMARY OPEN ANGLE 
GLAUCOMA AND OCULAR HYPERTENSION
Auzanneau N1, Touboul C1, Berdeaux G2
1Taylor Nelson Sofres, Montrouge, France; 2Alcon, Rueil-
Malmaison, France
OBJECTIVE: The aim of this study was to evaluate the
quality of life (QoL) of patients treated with a topical
anti-glaucoma drug in usual practice.
METHODS: A mailing was sent to 20,000 homes be-
longing to the Sofres panel (representative to the French
population according to the quota method) asking whether
one member of the family was treated for glaucoma. A
computer-assisted telephone interviewing system was
used to confirm self-reported glaucoma treatment, to de-
scribe the disease and its treatment, as well as medical
item consumption. Vision-related QoL was assessed with
the NEI-VFQ-25 and local tolerance and its QoL conse-
quences with the COMTOL.
RESULTS: 13,352 homes (66.7%) or 32,685 people an-
swered the mail. Five hundred eighty one people declared
they had glaucoma, leading to glaucoma and ocular hy-
pertension treatment prevalence of 1.8%, increasing with
age. From them, 204 people were selected at random.
Their NEI-VFQ-25 global score was high (80.2) showing
an overall good QoL. Two scores showed some deterio-
ration: general health (48.8) and driving (53.9). Ninety-
one (44.6%) patients changed their treatment at least
once: 55% due to poor efficacy and 35% for adverse
events. Being queried with the COMTOL, 62% of the
patients cited at least one local adverse event: 25% had
burning, 21% blurred vision, 20% tearing and 16% itch-
ing among others. Sixty percent of the patients visited
their ophthalmologist twice a year and 90% of the pa-
tients declared they were satisfied or very satisfied with
their treatment.
CONCLUSION: Based on a French representative sam-
ple, the overall satisfaction of patients treated with anti-
glaucoma drugs is high, although half of them have
changed their treatment at least once and the majority of
them declared an adverse event when queried. Eye related
QoL was not affected in the majority of the patients.
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THE SOCIETAL COST OF ATOPIC DERMATITIS 
IN GERMANY
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Atopic dermatitis (AD) is a common chronic dermatolog-
ical disease affecting mainly young children. According to
epidemiological studies, its prevalence has increased no-
tably over the last two decades.
OBJECTIVE: To assess the economic burden of AD in
Germany.
METHODS: A prevalence approach was adopted to
evaluate the societal cost of AD comprising direct medi-
cal costs, indirect costs, and out-of-pocket expenses. Not
included in this evaluation is the impact of AD on the pa-
tient and the family in terms of an impaired quality of
life. Data were collected from various sources: health sta-
tistics; labor statistics; literature; surveys, and an expert
panel of six dermatology specialists. All costs were ad-
justed to the year 1999. In order to explore the findings
in light of data variations, sensitivity analyses were per-
formed.
RESULTS: Based on an estimated base case population
of 2.45 million people suffering from AD, total annual
societal costs amount to DEM 1.32 billion (EUR 678 mil-
lion). Of these overall costs, DEM 636 million (48%) are
attributable to direct costs, DEM 428 million (32%) to
productivity losses (including time expenditures of par-
ents caring for their sick children), and DEM 257 million
(20%) to out-of-pocket expenses. The most important in-
dividual cost contributor is outpatient physician care
(28%), followed by time expenditure of parents (20%),
and out-of-pocket expenses (19%). Drug treatment ac-
counts for less than 10% of the overall costs. The average
per-patient societal cost of AD is around DEM 540 per
year. Sensitivity analysis showed a maximum variation in
yearly costs ranging between DEM 1.08 billion and DEM
1.61 billion when both prevalence and utilization esti-
mates are varied.
CONCLUSIONS: The chronic nature of AD coupled with
its high frequency represents a significant economic burden
to society in Germany. Based on these findings it can be
concluded that AD cannot be regarded as a minor illness.
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IS NON-CONTACT NORMOTHERMIC WOUND 
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TREATMENT OF STAGE 3 AND 4 
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OBJECTIVES: Chronic pressure ulcers are a significant
health problem for patients in long-term-care facilities.
The value of restoring quality of life following a pressure
ulcer injury has attracted new treatments. Non-contact
normothermic wound therapy (NNWT) (Warm-Up ther-
apy) is a semi-occlusive, moisture retentive wound cover
($240/wound cover/ 2 days) that is warmed to 38	C to
promote healing. The goal of this study was to examine
the incremental cost-effectiveness of NNWT relative to
the current standard of care for treatment of stage III and
IV pressure ulcers.
METHODS: A Markov cost-effectiveness, computer-sim-
ulation model with hypothetical patients was created.
The base case involved a 72-year-old man, living in a
nursing home, with a stage III ischial pressure ulcer.
Standard care was assumed to include moisture retentive
